Medications · Antioxidant & mitochondrial
Nicotinamide adenine dinucleotide for cellular energy support.
Why this needs to be personal
There is no FDA-approved NAD+ product. Every clinical use of NAD+ itself is compounded, and the trials that exist were each built around one route at one dose for one population. Trammell's oral NR pharmacokinetics, Yoshino's 250 mg oral NMN in prediabetic women, Pencina's MIB-626 polymorph, and Grant's single 6-hour IV NAD+ infusion in 11 healthy adults do not converge on a shared dosing schema. They tell you that blood NAD+ rises with supplementation. They do not tell you what dose, what route, or what cadence fits a specific patient with a specific clinical question, a specific tolerance for infusion-related flushing or chest tightness, and a specific reason their physician is reaching for this molecule at all.
Route and dose are the two axes a compounding pharmacy can move on for NAD+ specifically. IV infusion delivers a measured load over hours and lets the prescriber titrate by infusion rate when patients flush, feel pressure, or get nauseated. Intramuscular and subcutaneous injection trade peak for tolerability and let patients self-administer between clinician visits. Intranasal delivery is sometimes used when the target is CNS uptake without an infusion appointment. Oral capsules of NR or NMN sit in a different regulatory bucket as supplements, not 503A compounded drugs, but they remain an option in a layered protocol. Strength, frequency, and preservative profile all adjust to the patient. None of that flexibility lives in a manufactured product, because no manufactured product exists.
This is what pharmacy looked like before mass manufacturing arrived, and for NAD+ it is the only arrangement available. A prescriber writes the order for a named patient with a documented clinical reason. A licensed pharmacist prepares it. Modern sterility, ingredient sourcing, and traceability discipline keep the older model honest.
In brief
NAD+ stands for nicotinamide adenine dinucleotide. It is a small molecule that every cell in the body uses to convert food into energy and to run repair and signaling pathways. Levels of NAD+ in most tissues decline with age, which is why it has become a focus of aging research.
There is no FDA-approved NAD+ drug. The B-vitamin niacin (Niaspan) is FDA-approved, but for cholesterol, not for raising NAD+. Two newer precursors, nicotinamide riboside (NR, sold as NIAGEN) and nicotinamide mononucleotide (NMN), are sold as supplements 1320. Oral NR and NMN reliably raise blood NAD+ levels in clinical trials, but their effects on outcomes like strength, metabolism, and aging biomarkers have been mixed 619.
Intravenous NAD+ is sometimes marketed as a longevity or wellness drip. The published human evidence for IV NAD+ is limited to a single 6-hour infusion pharmacokinetic study plus case reports 15. RonanRx prepares compounded NAD+ under 503A only for patients with a documented clinical reason and a specific physician-directed protocol, not as a routine wellness product.
At a glance
Prescription review
NAD+ / NMN on this page is a 503A compounded preparation. Every dose is made on a prescription, for a named patient, by a licensed pharmacist. It is not a stocked, mass-manufactured product.
Real medicine, not gray market
A research-use-only website ships a vial from a warehouse. There is no prescription, no pharmacist, no facility inspection, and no way to recall the product if something is wrong with it. If the vial is mislabeled, contaminated, or under-potent, there is nobody whose license is at stake.
A 503A compounding pharmacy is the other thing. Your doctor writes the prescription. A licensed pharmacist, whose name is on the label, prepares the medicine in a facility the state inspects. If something goes wrong, there is a person and a license on the hook, and a documented chain of custody on every lot. That accountability is what makes it safe.
What it is
Nicotinamide adenine dinucleotide (NAD+) is a dinucleotide built from a nicotinamide ring and an adenine ring connected by a pair of ribose phosphates 6. It exists in cells as the oxidized form (NAD+) and the reduced form (NADH); together they form a redox couple that drives the dehydrogenase reactions of glycolysis, the tricarboxylic acid cycle, fatty-acid oxidation, and oxidative phosphorylation. A phosphorylated form, NADP+/NADPH, supports anabolic reductions and the antioxidant glutathione cycle.
Beyond redox, NAD+ is consumed (not merely shuttled) by three major enzyme families: the sirtuins (SIRT1, 7), which catalyze NAD+-dependent protein deacetylation and other acyl-removal reactions; the poly-ADP-ribose polymerases (PARPs), which transfer ADP-ribose to target proteins during DNA-damage signaling; and the CD38/CD157 NAD-glycohydrolases, which cleave NAD+ to generate calcium-mobilizing second messengers 619. SARM1, the nicotinamide-mononucleotide-activated NADase, drives programmed axon degeneration. Because these enzymes consume the substrate, intracellular NAD+ is in constant flux and depends on biosynthetic resupply.
Mammalian NAD+ biosynthesis runs through three principal routes: the de novo (kynurenine) pathway from tryptophan; the Preiss, Handler pathway from nicotinic acid; and the salvage pathways from nicotinamide, nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN) 6. NR and NMN are biosynthetic intermediates in the salvage route, and both have been developed as oral supplements intended to raise tissue NAD+. The vitamin B3 family, niacin (nicotinic acid), nicotinamide, and NR, provides the dietary feedstock for these pathways 132.
How it works
NAD+ functions in two distinct modes inside the cell 6. As a redox coenzyme it accepts and donates a pair of electrons, cycling between NAD+ and NADH to drive ATP synthesis through oxidative phosphorylation. As a signaling substrate it is consumed by the sirtuin, PARP, and CD38 enzyme families, which cleave the high-energy nicotinamide-ribose bond to do work on target proteins or to generate second messengers.
Cellular NAD+ levels reflect the balance between biosynthesis (de novo, Preiss, Handler, and salvage routes) and consumption (sirtuins, PARPs, CD38, SARM1) 19. When that balance shifts toward consumption, for instance with chronic DNA damage, inflammatory upregulation of CD38, or simple aging, total NAD+ declines and the NAD+-dependent enzymes lose substrate 13. The sirtuin-activation hypothesis proposes that restoring NAD+ rescues sirtuin function and downstream mitochondrial, metabolic, and stress-response benefits.
Oral NR and NMN raise blood and PBMC NAD+ levels in humans across multiple trials 2223. The connection from blood NAD+ rise to tissue-level NAD+ and to clinical endpoints is less consistent: Brakedal et al 8 14. (2022) showed brain NAD+ rises by 31P-MRS in early Parkinson disease patients on NR 21, while several trials in metabolic disease have failed to show improvements in insulin sensitivity, mitochondrial respiration, or body composition despite blood NAD+ rises 1617 6. Yoshino et al. (2021) is the principal positive metabolic-endpoint trial in NMN, with improved muscle insulin sensitivity in prediabetic postmenopausal women 20 9.
Research history
NAD+ was discovered by Arthur Harden and William Young in 1906 as a 'cozymase' factor required for yeast fermentation; the structure was solved by Otto Warburg and Hans von Euler-Chelpin in the 1930s, and the connection to vitamin B3 (niacin) was made by Conrad Elvehjem in 1937 when nicotinamide was shown to resolve canine black-tongue disease. Niacin entered clinical use for pellagra by the early 1940s. The vitamin chemistry and biosynthetic pathways were worked out across the 1950s and 1960s 13.
Two pre-NAD-aging human dermatologic and immunologic precedents matter for the modern safety case. The European Nicotinamide Diabetes Intervention Trial (ENDIT) randomized 552 islet-autoantibody-positive first-degree relatives at risk for type 1 diabetes to nicotinamide vs placebo for a median 5 years and found no diabetes-prevention effect, but established long-term high-dose nicotinamide tolerability across a multi-year exposure 35. The ONTRAC trial 36 randomized 386 patients with prior nonmelanoma skin cancers to oral nicotinamide 500 mg twice daily and showed a 23% reduction in new lesions 36, following earlier phase II actinic-keratosis trials 37 and consolidated in reviews of the dermatologic literature 38.
The modern NAD+/aging story begins with Bieganowski and Brenner's 2004 identification of nicotinamide riboside (NR) as a distinct NAD+ precursor vitamin 29, followed by Belenky et al. (2007) showing NR extends lifespan via Sir2 in yeast 30 and the structural characterization of the NR kinase enzymes (NRK1/NRK2) by Tempel et al. (2007) 2. Imai and Guarente consolidated the sirtuin, NAD+ axis as a unifying framework in 2010 and 2014 reviews 316. Mendelsohn and Larrick (2014) connected NAD+ restoration directly to reversible skeletal-muscle aging 34. Cantó et al. (2012) demonstrated NR-driven SIRT1/SIRT3 activation and protection from diet-induced obesity in mice 32, and Mouchiroud et al. (2013) linked the NAD+/sirtuin axis to lifespan extension via the mitochondrial UPR in C. elegans 33. Mills et al. (2016) demonstrated that long-term oral NMN administration mitigated age-associated physiological decline across multiple organ systems in mice, providing the preclinical foundation for human NMN trials 10; Yoshino et al. (2011) had earlier shown that NMN treated diet- and age-induced diabetes in mice 4. The aging-NAD-decline mechanism was nailed to CD38 upregulation by Camacho-Pereira et al. (2016) 7, with the CD38 inhibitor 78c later proving the principle pharmacologically in aged mice 4041; brain-specific NAD+ decline became a separate review focus 44.
Human translation of NR followed quickly. Trammell et al. (2016) first characterized oral NR pharmacokinetics in humans, including the methyl-group sink question raised by extensive N-methylnicotinamide excretion 9. Airhart et al. (2017) added an open-label PK study 11. Martens et al. (2018) ran the first chronic NR trial in healthy middle-aged and older adults 13; Dollerup et al. (2018, AJCN) ran the first parallel-group RCT of NR in obese, insulin-resistant men with detailed safety reporting 42, and Conze et al. (2019) confirmed long-term tolerability and NAD+ elevation in overweight adults 14. Elhassan et al. (2019) provided the first muscle-biopsy demonstration that NR raises the intramuscular NAD+ metabolome in aged humans 43. Remie et al. (2020) and Dollerup et al. (2020) tested NR in further metabolic-disease cohorts with mostly null endpoint findings despite NAD+ rises 1617. Jensen et al. (2022) found that NR plus pterostilbene did not accelerate muscle injury recovery in older adults 48. Pirinen et al. (2020) reported the only positive functional-endpoint NAD+-repletion trial to date, niacin (not NR) restored systemic NAD+ levels and improved muscle performance in adult-onset mitochondrial myopathy 46.
Human NMN translation has been slower but ongoing. Irie et al. (2020) reported the first single-dose human NMN safety study in Japanese men 45. Yoshino M et al. (2021, Science) reported the first positive metabolic endpoint with NMN in prediabetic postmenopausal women 20. Liao et al. (2021) showed dose-dependent aerobic-capacity improvement on NMN in amateur runners 47. Igarashi et al. (2022) replicated NMN tolerability and muscle-function gains in older Japanese men 22. Pencina et al. (2023) characterized the MIB-626 microcrystalline NMN polymorph 23. Yamaguchi et al. (2024) extended the NMN safety profile to 12 weeks in middle-aged Japanese men 50. NMN is currently outside the US dietary-supplement pathway after the FDA's reclassification.
The Parkinson disease translation began with Brakedal et al.'s 2022 NADPARK trial 21 and continued with Berven et al.'s 2023 NR-SAFE trial of high-dose NR (3000 mg/day) 49; a longer-duration efficacy trial (NO-PARK) is in progress. The cardiac NAD+ literature is largely preclinical: Diguet et al. (2018, Circulation) showed NR preserves cardiac function in a mouse model of dilated cardiomyopathy 39, and Peclat et al. (2024) extended CD38-inhibition cardioprotection to doxorubicin-induced cardiotoxicity 51. The first peer-reviewed human PK data on IV NAD+, Grant et al. (2019), described a 6-hour infusion protocol in 11 healthy adults 15; this remains the principal published reference for IV NAD+ used in clinical compounding settings.
Timeline
Natural role
NAD+ is one of the most abundant non-protein molecules in living cells. Tissue concentrations are in the micromolar range and turnover is rapid, on the order of minutes to hours depending on cell type. The dinucleotide sits at the intersection of metabolism (as the dominant redox carrier of glycolysis and oxidative phosphorylation) and signaling (as substrate for sirtuins, PARPs, and CD38) 6.
The aging-relevant biology has three interlocking arms. First, mitochondrial function depends on the NAD+/NADH redox state; chronic NAD+ depletion compromises ATP synthesis. Second, sirtuin signaling integrates NAD+ availability with energy status: when NAD+ is plentiful, sirtuins deacetylate substrates that promote oxidative metabolism, stress resistance, and DNA repair 6. Third, CD38, the dominant NAD+-degrading enzyme in tissue, rises with age and inflammation, accelerating the decline 719. The convergence of these arms is the framework that motivated the clinical development of NR and NMN as NAD+ precursors and the off-label use of IV NAD+ in compounded settings.
Clinical contexts studied
Background biology, not an FDA-approved indication.
Human tissue NAD+ declines with age across skin, brain, liver, skeletal muscle, and adipose 5. The decline is driven in part by CD38 upregulation 7 and is the rationale for NAD+ precursor and parenteral NAD+ supplementation strategies. No regulatory endpoint exists for 'restoring NAD+'; this is a research framework, not a treatment indication 619.
Pharmacokinetic and biomarker endpoint; clinical endpoint effects mixed.
Trammell (2016) 9, Airhart (2017) 11, Martens (2018) 13, and Conze (2019) 14 consistently show that oral NR raises blood/PBMC NAD+ in dose-dependent fashion with no significant safety signal across short- to medium-term dosing. Remie (2020) 16 and Dollerup (2020) 17 tested NR in metabolic-disease cohorts and found null effects on insulin sensitivity and mitochondrial respiration despite biomarker rises. NIAGEN holds GRAS status as a dietary supplement, not drug status 25.
Emerging, small RCTs with one positive metabolic endpoint.
Yoshino M et al. (Science 2021) 20 randomized 25 prediabetic postmenopausal women to NMN 250 mg/day for 10 weeks and showed improved muscle insulin sensitivity on hyperinsulinemic-euglycemic clamp, the first positive metabolic endpoint in a human NMN trial. Igarashi (2022) 22 showed NMN raised blood NAD+ and improved gait/grip in older men. Pencina (2023) 23 characterized the MIB-626 polymorph. NMN is not GRAS in the United States; FDA has declined to permit NMN sale as a dietary supplement.
Phase I trial endpoints; not an FDA-approved indication.
The NADPARK trial 21 21 randomized 30 adults with newly diagnosed Parkinson disease to NR 1000 mg/day or placebo for 30 days. Brain NAD+ on 31P-MRS rose in NR-treated patients; cerebrospinal fluid and plasma NAD-metabolome shifts were consistent. Clinical endpoints in this short trial were exploratory; a longer-duration efficacy trial (NR-SAFE / NO-PARK) is ongoing.
Tier-3 emerging. Published peer-reviewed human evidence is essentially one pharmacokinetic pilot plus case-series; broader clinical use is anecdotal and unstandardized.
Grant et al. (2019) 15 is the principal peer-reviewed human PK study: an open-label 6-hour infusion of 750 mg NAD+ in 11 healthy adults, with serial plasma and urine sampling. Plasma NAD+ rose with delayed kinetics consistent with extensive extracellular metabolism to nicotinamide and salvage-pathway metabolites. No controlled clinical-endpoint trial of IV NAD+ in addiction medicine, post-acute recovery, or general wellness has been published. RonanRx position: legitimate when a patient and physician have a specific protocol context; not a DTC longevity product.
The strongest positive functional-endpoint NAD+-repletion result in humans is from niacin in a rare disease cohort, not an FDA-approved indication.
Pirinen et al. (2020, Cell Metabolism) 46 gave niacin titrated to 750, 1000 mg/day for 10, 16 months in 10 adults with adult-onset mitochondrial myopathy and progressive external ophthalmoplegia. Systemic NAD+ was restored to control levels, muscle strength and mitochondrial biogenesis increased, and the trial provides the principal human precedent that NAD+-axis repletion can translate to a functional clinical endpoint, using nicotinic acid rather than NR or NMN.
Preclinical. No randomized human cardiac endpoint trial of NR, NMN, or IV NAD+ has reported.
Diguet et al. (2018, Circulation) 39 showed oral NR preserves cardiac function, restores myocardial NAD+, and improves survival in a mouse model of dilated cardiomyopathy. Peclat et al. (2024, Cardiovasc Res) 51 extended CD38 inhibition cardioprotection to doxorubicin-induced cardiotoxicity. The Chini lab CD38/NAD pharmacology literature 4140 frames the mechanistic case. Human translation has not yet reported.
Tier 1, 2 evidence for oral nicotinamide in high-risk patients, distinct from NR/NMN/IV NAD+ but the strongest randomized endpoint trial in the vitamin-B3 family.
The ONTRAC trial 36 36 randomized 386 high-risk patients to oral nicotinamide 500 mg twice daily and showed a 23% reduction in new nonmelanoma skin cancers at 12 months. Surjana et al. (2012) 37 showed a 29, 35% reduction in actinic keratoses on the same regimen. The dermatology literature is summarized in Snaidr 2019 38. This is oral nicotinamide chemoprevention, not an NAD+ precursor mechanism in the NR/NMN sense, but the strongest randomized endpoint trial of any B3-family compound and the principal long-term-exposure safety dataset.
Negative endpoint trial, included for honesty about the historical vitamin-B3 evidence base.
The ENDIT trial 35 35 randomized 552 islet-autoantibody-positive first-degree relatives at risk for type 1 diabetes to oral nicotinamide vs placebo for a median 5 years. Nicotinamide did not prevent or delay onset of type 1 diabetes. The trial nonetheless established long-term high-dose nicotinamide tolerability in adolescents and adults, which bounds the chronic-exposure safety envelope for the broader B3 family.
Off-label use
Not supported by published controlled trials; RonanRx does not dispense for DTC wellness use.
Public marketing of IV NAD+ for 'longevity', 'energy', or generalized wellness is not supported by published controlled human trials. The single PK pilot 15 establishes that infused NAD+ enters the systemic circulation and is metabolized, but does not demonstrate clinical benefit. RonanRx 503A does not compound IV NAD+ for DTC wellness drip protocols; dispensing requires a documented patient-specific clinical indication and physician-directed protocol.
Compounded use
RonanRx dispenses compounded NAD+, typically as sterile injectable solutions for IV infusion, IM, or SC administration, under 503A on patient-specific prescriptions only. Oral NR and NMN are dietary supplements outside the compounding pathway; the 503A scope at RonanRx covers parenteral NAD+ preparations and, where prescribed, parenteral nicotinamide 26 913.
The clinical evidence framing is important: the only peer-reviewed human PK study of IV NAD+ is Grant et al 26. (2019) 15. Beyond that, the published literature on IV NAD+ for clinical conditions is anecdotal, case series, observational reports, and unpublished clinic protocols. This is a true Tier-3 emerging-evidence compound. RonanRx compounds IV/IM/SC NAD+ when a patient and physician have a specific protocol context (for example, addiction-medicine-adjacent protocols, post-acute recovery contexts, or other clinician-supervised use cases) and when the prescriber documents the clinical rationale 14. RonanRx does not market or dispense compounded NAD+ as a DTC longevity product 20.
Because the precursors NR and NMN are dietary supplements with substantial published PK and safety literature, a prescriber considering NAD+-axis therapy may reasonably evaluate oral precursors as a first-line option before parenteral NAD+ 26 23. The pharmacist review process documents this consideration.
Formulations and routes
| Form | Concentration | Description |
|---|---|---|
| Sterile NAD+ injection (compounded, IV/IM/SC) | Custom; commonly 100 mg/mL for IV infusion preparations, with single-dose volumes calibrated to a 250, 1000 mg/dose protocol depending on indication and clinician direction | Sterile aqueous solution of NAD+ disodium prepared under USP <797> standards for sterile compounding on a patient-specific prescription. Container closure, excipient profile, and concentration are documented per batch and matched to the prescriber's protocol.27 |
| Oral NR (nicotinamide riboside chloride) | Typically 100, 300 mg per capsule; supplement-grade NIAGEN product | Oral NR is a GRAS dietary supplement (NIAGEN, ChromaDex) outside the 503A pathway. Included here for completeness of the NAD+ axis; not compounded by RonanRx.259 |
| Oral NMN | Typically 125, 300 mg per capsule | Oral NMN is sold as a supplement in some jurisdictions; FDA has declined to permit NMN sale as a dietary supplement in the United States after its prior investigation as a pharmaceutical. Included here for completeness; not compounded by RonanRx.20 |
Routes used in published literature: intravenous, intramuscular, subcutaneous, oral.
Dosing
| Route | Population | Range | Duration | Study type |
|---|---|---|---|---|
| Intravenous | Adults receiving clinician-directed IV NAD+ infusion under a specific protocol | 250, 1000 mg per infusion in 250, 500 mL diluent infused over 2, 6 hours; clinician-directed scheduling. Grant et al. (2019) used a single 750 mg dose infused over 6 hours in healthy adults. | Per clinician protocol; not standardized in controlled trials | Open-label pharmacokinetic pilot plus uncontrolled case-series15 |
| Subcutaneous or intramuscular | Adults under clinician-directed compounded NAD+ injection protocol | 50, 200 mg per injection; clinician-directed scheduling | Per clinician protocol | Anecdotal / case-series only; no controlled human trials15 |
| Oral (NR, supplement, included for reference) | Adults | 300, 1000 mg/day across published RCTs | 6, 12 weeks in published trials | Multiple randomized controlled trials913141617 |
| Oral (NMN, supplement, included for reference) | Adults | 250 mg/day in the principal published RCTs; up to 1000, 2000 mg/day in MIB-626 dose-ranging | 10, 12 weeks in published trials | Small randomized controlled trials202223 |
There is no FDA-approved labeled dose for NAD+, NR, or NMN. IV NAD+ dosing in clinic protocols varies widely (typically 250, 1000 mg per infusion over 2, 6 hours, sometimes repeated daily over 5, 10 days for an addiction-medicine-style course) and is not standardized in controlled trials. The only published peer-reviewed human PK protocol is Grant et al. (2019): a single 750 mg infusion over 6 hours in 11 healthy adults 15.
RonanRx does not promote or dispense a specific IV NAD+ protocol. Compounded NAD+ is prepared to the prescriber's order at the concentration and total dose specified, and pharmacist review confirms that a clinical rationale and protocol are documented. Prescribers considering parenteral NAD+ should be aware that the published evidence base is essentially one PK pilot plus uncontrolled case-series, the evidence is qualitatively different from the oral NR/NMN trial literature.
Doses listed are literature context, not patient instructions. Dosing decisions are made by the prescribing doctor and tailored to the individual patient.
Safety
Oral NR has been well-tolerated in published trials. Dollerup et al. (2018, AJCN) 42 reported no serious adverse events in obese, insulin-resistant men on NR 1000 mg twice daily for 12 weeks. Conze et al. (2019) 14 reported no serious adverse events on NR up to 600 mg/day for 8 weeks; Martens et al. (2018) 13 reported clean tolerability at 1000 mg/day for 6 weeks; Remie et al. (2020) 16 and Dollerup et al. (2020) 17 reported tolerable profiles at 1000 mg/day for 6, 12 weeks; Elhassan et al. (2019) 43 reported tolerability with reductions in inflammatory markers in aged adults. Mild gastrointestinal symptoms (nausea, flushing, headache) have been reported sporadically. NIAGEN holds GRAS status 25. Oral nicotinamide has been administered at 1.2 g/day for a median 5 years in the ENDIT type 1 diabetes prevention trial 35 and 1 g/day for 12 months in the ONTRAC skin-cancer chemoprevention trial 36 without serious safety signals, bounding the long-term-exposure envelope for the B3 family 20.
Oral NMN trials reported tolerability without serious adverse events. Irie et al. (2020) 45 noted modest rises in serum bilirubin and creatinine after single NMN doses up to 500 mg, motivating downstream surveillance of these markers, but the changes were not clinically significant. Trial durations remain short (4, 12 weeks) and sample sizes small (10, 48 participants), which limits adverse-event characterization. Yamaguchi 2024 50 extends NMN safety to 12 weeks at 250 mg/day in middle-aged men.
A theoretical concern specific to NR pharmacology is the methyl-group sink. Trammell et al. (2016) 9 showed that oral NR is extensively methylated to N-methylnicotinamide and excreted; chronic high-dose precursor loading could in principle compete with other methylation pathways (homocysteine remethylation, neurotransmitter synthesis). No clinical harm has been documented in published trials at typical doses, but this is the most-discussed theoretical signal for high-dose chronic NR or nicotinamide 22.
IV NAD+ safety data are sparse. Grant et al. (2019) 15 reported the infusion was 'tolerable' in 11 healthy adults but participants reported pressure or chest tightness during rapid infusion phases, a finding consistent with widely reported clinic experience that IV NAD+ must be infused slowly to avoid discomfort. No controlled long-term safety study of IV NAD+ exists. The high-dose NR-SAFE Parkinson trial 49 establishes safety of NR at 3000 mg/day for 4 weeks but does not translate to the parenteral route. Theoretical concerns relevant to the NAD+ axis include potential interactions with chemotherapy (PARP-dependent DNA-damage signaling), potential nicotinamide accumulation with high or repeated dosing, and unknown effects of chronically elevated NAD+ on CD38- and sirtuin-mediated immunometabolism 41; none of these are documented as clinical harms in the published literature, but the absence of large controlled trials means absence of evidence is not evidence of safety 4723.
RonanRx framing: compounded IV/IM/SC NAD+ is a Tier-3 emerging-evidence preparation. The safety profile of oral NR and NMN is reasonably well-characterized for the dose ranges and durations studied 23. The safety profile of IV NAD+ in routine clinical use is not well-characterized and must be considered in the prescriber's risk-benefit assessment.
There is no FDA-labeled contraindication list for NAD+, NR, or NMN because no FDA-approved drug product exists in these forms. Prescriber discretion applies. Reasonable cautions include: active malignancy receiving PARP-targeted or DNA-damaging chemotherapy (theoretical interaction via NAD+-dependent DNA-damage response); known hypersensitivity to the active ingredient or compounded preparation excipients; pregnancy and lactation (no published controlled human data); and severe hepatic or renal impairment (no dedicated PK studies of parenteral NAD+ in these populations).
Niacin (nicotinic acid) has its own labeled contraindications (active liver disease, active peptic ulcer, arterial bleeding) under the Niaspan label 24; these are specific to niacin and do not necessarily transfer to NR, NMN, or NAD+.
Drug-interaction data for NAD+, NR, and NMN are limited. Theoretical interactions to consider: (1) chemotherapy agents that engage PARP-mediated DNA damage signaling (PARP is an NAD+-consuming enzyme); (2) immunosuppressants and other agents that modulate CD38 or sirtuin pathways; (3) other vitamin-B3 forms (niacin, nicotinamide) where additive nicotinamide load could matter at high doses; and (4) agents with overlapping vascular or flushing effects (niacin in particular is associated with prostaglandin-mediated flushing, distinct from NR/NMN) 24.
No clinically significant CYP-mediated drug-drug interactions have been characterized for NR, NMN, or parenteral NAD+ in published studies 19.
Oral NR: in the principal RCTs, the most commonly reported adverse events are mild gastrointestinal symptoms (nausea, dyspepsia), headache, and occasional flushing. Adverse-event-driven discontinuation rates have been low and comparable to placebo. No serious adverse events attributable to NR have been reported in trials up to 12 weeks at doses up to 1000 mg/day 17.
Oral NMN: in the published trials 202223, tolerability has been reported as good with no serious adverse events. Trial durations have been short (10, 12 weeks) and sample sizes small (25, 80 participants), which limits adverse-event characterization.
IV NAD+: Grant et al. (2019) 15 reported infusion-related transient discomfort (pressure sensation, mild chest tightness) particularly during rapid infusion phases, mitigated by slowing the infusion rate. Headache, nausea, and flushing during infusion are commonly described in clinic experience. The published evidence base does not characterize a controlled adverse-event profile for repeated or chronic IV NAD+ use 131416.
Monitoring
There is no standard monitoring protocol for NAD+ supplementation or infusion. Reasonable baseline assessment depends on the indication and route: a clinical history including current medications and any prior NAD+-axis supplementation; for parenteral protocols, a focused review of the protocol's stated indication and duration; and patient education on infusion-related side effects (pressure, flushing, nausea).
Blood NAD+ levels can be measured but are not standardized clinically and the interpretation in routine practice is unclear. Routine laboratory monitoring (CBC, comprehensive metabolic panel) is appropriate per clinician judgment but is not required by any regulatory standard for compounded NAD+.
Special populations
No published controlled human data on NR, NMN, or parenteral NAD+ in pregnancy. Use during pregnancy is not recommended outside of a specific clinician-directed protocol with documented risk-benefit assessment.
No published data on NAD+, NR, or NMN in human milk or effects on the breastfed infant. Use during lactation is not recommended outside of a specific clinician-directed protocol.
No published controlled trials in pediatric populations. Compounded NAD+ is not prepared for pediatric use at RonanRx absent a specific clinician-directed protocol and documented clinical reason.
The principal RCTs of oral NR and NMN enrolled middle-aged and older adults and reported tolerability comparable to younger cohorts 132223. Parenteral NAD+ has not been studied in dedicated geriatric trials.
No dedicated PK studies in renal impairment for NR, NMN, or parenteral NAD+. NAD+ metabolites (nicotinamide, methylnicotinamide) are renally cleared; theoretical accumulation in renal impairment is plausible but has not been characterized clinically.
No dedicated PK studies in hepatic impairment. NAD+ biosynthesis is hepatically active, so altered hepatic function may affect precursor metabolism, but published guidance is not available.
Evidence quality
The NAD+ axis is one of the most active areas of aging biology, with strong mechanistic and preclinical underpinning but a mixed human translation. The mechanistic case, that tissue NAD+ declines with age 5, that CD38 drives much of the decline 74140, that sirtuins are NAD+-dependent and metabolically important, that the NAD+/sirtuin axis modulates lifespan via the mitochondrial UPR 33, that NR rescues high-fat-diet metabolic dysfunction in mice 32, that long-term NMN mitigates age-associated decline across organ systems in mice 10, and that NR preserves cardiac function in mouse models of dilated cardiomyopathy 39, is consistent and well-supported.
Human evidence for oral NAD+ precursors is at the small-RCT scale and totals roughly a dozen randomized trials between NR and NMN as of 2026 14. Oral NR reliably raises blood/PBMC NAD+ in dose-dependent fashion across multiple trials and Elhassan 2019 confirmed intramuscular NAD+ metabolome elevation on muscle biopsy in aged humans 43 4523. Effects on clinical endpoints have been mixed: NADPARK 21 showed brain NAD+ rise in Parkinson disease and the follow-on NR-SAFE 49 confirmed high-dose tolerability, but firm clinical efficacy awaits the NO-PARK trial 6. Metabolic-disease cohorts on NR 421617 showed null effects on insulin sensitivity and mitochondrial respiration despite NAD+ rises. The NR+pterostilbene muscle-injury trial 48 was also null 1913. The strongest positive functional-endpoint NAD+-repletion result in humans is not from NR or NMN but from niacin restoring systemic NAD+ levels and improving muscle performance in adult-onset mitochondrial myopathy 46 318.
Oral NMN trials are smaller still, with positive endpoints in muscle insulin sensitivity 20, aerobic capacity 47, and muscle function 22, and consistent biomarker confirmation of blood NAD+ rise across the cohort. Tolerability is good through 12 weeks and 250 mg/day; longer-duration and higher-dose data are limited. The vitamin-B3 family safety case at chronic high doses is anchored by the multi-year ENDIT trial of nicotinamide 1.2 g/day in adolescents and adults 35 and the ONTRAC trial of nicotinamide 1 g/day for 12 months 363738, these are not NAD+-precursor trials in the modern sense but they bound the chronic-exposure safety envelope for the broader vitamin family.
Human evidence specifically for IV NAD+ in clinical use is essentially anecdotal/case-series. The Grant 2019 pilot 15 is the principal peer-reviewed human PK reference. No controlled clinical-endpoint trial of IV NAD+ in addiction medicine, post-acute recovery, neurodegenerative disease, or general wellness has been published. The mechanistic biology, that infused NAD+ is largely metabolized extracellularly to nicotinamide and downstream precursors before tissue uptake 15, suggests that any benefit of IV NAD+ over equivalent oral precursor exposure has yet to be demonstrated in controlled human trials 911. RonanRx therefore classifies parenteral NAD+ as Tier-3 emerging evidence and dispenses on patient-specific prescription with documented clinician rationale only 50. The growing CD38-inhibitor literature 405141 is a distinct pharmacologic strategy not yet in human clinical trials.
Major studies
| Study | Design | Participants | Duration | Finding |
|---|---|---|---|---|
| Trammell et al. (2016, Nature Communications), first human PK of oral NR | Mouse PK plus single-ascending-dose human study of nicotinamide riboside | — | Acute (single oral dose escalation) | Oral NR is uniquely orally bioavailable; dose-dependent elevation of blood NAD+ metabolome in humans 9. Established NR as a tractable oral NAD+ precursor distinct from niacin and nicotinamide. |
| Martens et al. (2018, Nature Communications), chronic NR in healthy older adults | Randomized, double-blind, placebo-controlled crossover trial of NR 1000 mg/day in healthy middle-aged and older adults | 30 | 6 weeks per arm | NR roughly doubled PBMC NAD+ and reduced systolic blood pressure modestly; tolerability comparable to placebo 13. |
| Conze et al. (2019, Scientific Reports), long-term NR tolerability | Randomized, double-blind, placebo-controlled trial of NR (NIAGEN) 100, 300, and 600 mg/day in adults with overweight | 140 | 8 weeks | Dose-dependent elevation of whole-blood NAD+; no significant adverse-event signal vs placebo. Anchors GRAS safety case for NR 14. |
| Remie et al. (2020, AJCN), NR in adults with obesity | Randomized, double-blind, placebo-controlled crossover trial of NR 1000 mg/day in adults with obesity | 13 | 6 weeks per arm | NR raised NAD+ metabolome and shifted body composition (reduced acetylcarnitines) but did not improve insulin sensitivity, mitochondrial function, or substrate metabolism 16. |
| Dollerup et al. (2020, J Physiol), NR in obese insulin-resistant men | Randomized, double-blind, placebo-controlled parallel-group trial of NR 1000 mg/day in obese insulin-resistant men | 40 | 12 weeks | NR did not alter mitochondrial respiration, content, or morphology in skeletal muscle; further evidence that NAD+ blood rise does not consistently translate to tissue-level functional change 17. |
| Yoshino M et al. (2021, Science), NMN in prediabetic women | Randomized, double-blind, placebo-controlled trial of NMN 250 mg/day in prediabetic postmenopausal women | 25 | 10 weeks | NMN improved muscle insulin sensitivity on hyperinsulinemic-euglycemic clamp, first positive human metabolic-endpoint trial of an NAD+ precursor 20. |
| Igarashi et al. (2022, npj Aging), NMN in older men | Randomized, double-blind, placebo-controlled trial of NMN 250 mg/day in healthy older men | 42 | 12 weeks | Blood NAD+ elevation with modest improvements in muscle function (gait speed, grip strength) 22. |
| Pencina et al. (2023, J Gerontol A), MIB-626 NMN polymorph | Randomized, double-blind, placebo-controlled dose-ranging trial of MIB-626 (microcrystalline NMN) 1000, 2000 mg/day in middle-aged and older adults | — | 14 days | Dose-dependent elevation of whole-blood and PBMC NAD+ and shifts in the NAD+ metabolome 23. |
| Brakedal et al. (2022, Cell Metabolism), NADPARK | Randomized phase I trial of NR 1000 mg/day in adults with newly diagnosed Parkinson disease | 30 | 30 days | Brain NAD+ rise on 31P-MRS; consistent CSF and plasma metabolome shifts; established the disease-model NAD+ rise rationale that motivates longer-duration trials 21. |
| Grant et al. (2019, Front Aging Neurosci), IV NAD+ pilot PK | Open-label pilot pharmacokinetic study of a single 750 mg NAD+ intravenous infusion over 6 hours in healthy adults | 11 | Single 6-hour infusion with serial plasma and urine sampling | Plasma NAD+ rose with delayed kinetics; metabolite signature in plasma and urine consistent with extensive extracellular metabolism 15. Tolerable when infused slowly. This is the principal peer-reviewed human PK reference for IV NAD+ in the compounded-pharmacy literature. |
| Massudi et al. (2012, PLoS ONE), Age-related NAD+ decline in human tissue | Cross-sectional measurement of NAD+, NADH, NAD/NADH ratio, and PARP activity in human skin samples across the adult lifespan | — | — | Documented decline in NAD+ with age and rising oxidative-stress markers, a key human reference for the aging-decline framework 5. |
| Camacho-Pereira et al. (2016, Cell Metabolism), CD38 mechanism | Preclinical mechanistic study of CD38 in age-related NAD+ decline using CD38-knockout mice and tissue biochemistry | — | — | CD38 upregulation drives age-related NAD+ decline via a SIRT3-dependent mitochondrial dysfunction mechanism; CD38 knockout protects against the decline 7. |
| Mills et al. (2016, Cell Metabolism), Long-term NMN in mice | 12-month oral NMN administration study across multiple organ systems in C57BL/6 mice | — | — | NMN mitigated age-associated physiological decline in energy metabolism, insulin sensitivity, eye function, bone density, and gene-expression profiles; preclinical foundation for human NMN trials 10. |
| Yoshino et al. (2011, Cell Metabolism), NMN in diet/age-induced diabetic mice | Preclinical NMN intervention in diet- and age-induced diabetes mouse models | — | — | Intraperitoneal NMN treated impaired glucose tolerance and lipid abnormalities; preclinical rationale for human NMN trials 4. |
| Airhart et al. (2017, PLoS ONE), Open-label NR PK | Open-label, non-randomized PK study of oral NR in healthy adults | 8 | 8 days | Confirmed dose-related blood NAD+ rise on oral NR dosing; supported the chronic-dosing trials that followed 11. |
| Dollerup et al. (2018, Am J Clin Nutr), NR safety and insulin sensitivity in obese men | Randomized, double-blind, placebo-controlled parallel-group trial of NR 1000 mg twice daily in obese, insulin-resistant men | 40 | 12 weeks | NR was well-tolerated with no serious adverse events. No improvement in insulin sensitivity (hyperinsulinemic-euglycemic clamp), endogenous glucose production, lipolysis, or substrate oxidation despite elevated NAD+ metabolome. Provided the primary safety dataset alongside Conze 2019 42. |
| Elhassan et al. (2019, Cell Reports), NR in aged human skeletal muscle | Randomized, double-blind, placebo-controlled crossover trial of NR 1000 mg/day in aged men with muscle biopsy | 12 | 21 days per arm | NR augmented the skeletal muscle NAD+ metabolome and induced transcriptomic anti-inflammatory signatures; circulating IL-6 and other inflammatory markers fell 43. First trial demonstrating intramuscular NAD+ metabolome elevation on oral NR in aged humans. |
| Jensen et al. (2022, JCI Insight), NR+pterostilbene in muscle injury | Randomized, double-blind, placebo-controlled trial of NR plus pterostilbene in elderly participants undergoing experimental muscle injury and recovery | 32 | Pre/post injury protocol | Combined NR+pterostilbene did not accelerate muscle regeneration or improve recovery markers vs placebo despite NAD+ metabolome rise 48. Adds to the body of null-functional-endpoint NR trials. |
| Liao et al. (2021, J Int Soc Sports Nutr), NMN in amateur runners | Randomized, double-blind, placebo-controlled, dose-ranging trial of NMN 300, 600, or 1200 mg/day in amateur male runners under exercise training | 48 | 6 weeks | Dose-dependent improvement in aerobic capacity (VO2max-derived ventilatory thresholds) in the NMN groups vs placebo 47. One of the first non-Japanese, non-Western academic NMN trials with a functional endpoint. |
| Irie et al. (2020, Endocrine Journal), Single-dose NMN safety in Japanese men | Single-blind, single-ascending-dose trial of NMN 100, 250, and 500 mg oral in healthy Japanese men | 10 | Single dose with 5-hour PK sampling | NMN was well-tolerated up to 500 mg; no clinically significant changes in vital signs, ophthalmologic, or laboratory parameters. Serum bilirubin and creatinine rose modestly, motivating downstream safety surveillance. First published human safety report on oral NMN 45. |
| Yamaguchi et al. (2024, Endocrine Journal), Long-term NMN safety in middle-aged Japanese men | Randomized, double-blind, placebo-controlled trial of NMN 250 mg/day in middle-aged Japanese men | 30 | 12 weeks | NMN raised blood NAD+ and was well-tolerated with no serious adverse events; sleep quality and modest metabolic markers shifted favorably. Extends the Igarashi NMN safety profile to a longer follow-up 50. |
| Diguet et al. (2018, Circulation), NR in dilated cardiomyopathy mouse model | Preclinical NR feeding study in a serum response factor (SRF) knockout mouse model of dilated cardiomyopathy | — | — | NR supplementation preserved cardiac function, restored myocardial NAD+, and improved survival vs untreated mutants 39. Provides the principal preclinical rationale for NAD+ precursor trials in heart failure. |
| Tarragó et al. (2018, Cell Metabolism), CD38 inhibitor 78c reverses age-related NAD+ decline | Preclinical pharmacology of the small-molecule CD38 inhibitor 78c in aged mice | — | — | 78c reversed age-related tissue NAD+ decline, improved glucose tolerance, muscle function, and exercise capacity in aged mice 40. Established CD38 inhibition as an alternative pharmacologic strategy to precursor loading for restoring NAD+. |
| Peclat et al. (2024, Cardiovasc Res), CD38 inhibition in doxorubicin cardiotoxicity | Preclinical ecto-CD38 inhibition in a mouse model of doxorubicin-induced cardiotoxicity | — | — | Ecto-CD38 inhibition modulated cardiac NAD+ metabolism and protected against doxorubicin cardiotoxicity 51. Extends the CD38-targeting hypothesis from aging to drug-induced cardiac injury. |
| Pirinen et al. (2020, Cell Metabolism), Niacin in mitochondrial myopathy | Open-label phase II trial of niacin (nicotinic acid) titrated to 750, 1000 mg/day in adult-onset mitochondrial myopathy with progressive external ophthalmoplegia | 10 | 10, 16 months | Niacin restored systemic NAD+ to control levels and increased muscle strength and mitochondrial biogenesis in patients 46. The first human NAD+-repletion trial in a primary mitochondrial disease with a positive functional endpoint. |
| Cantó et al. (2012, Cell Metabolism), NR protects against diet-induced obesity in mice | Preclinical study of oral NR in high-fat-diet-fed C57BL/6 mice | — | — | NR enhanced oxidative metabolism in muscle and brown adipose, activated SIRT1 and SIRT3, and protected against high-fat-diet obesity and insulin resistance 32. Key preclinical foundation for human NR metabolic trials. |
| Mouchiroud et al. (2013, Cell), NAD+/sirtuin axis and longevity via UPR-mt and FOXO | Mechanistic study in C. elegans and mammalian cells of NAD+ repletion and PARP inhibition | — | — | NAD+ repletion activated the mitochondrial unfolded protein response (UPR-mt) and FOXO signaling in a SIR-2.1-dependent manner; extended lifespan in worms 33. Established the UPR-mt as a downstream effector of NAD+/sirtuin signaling in aging. |
| Bieganowski & Brenner (2004, Cell), Discovery of NR as an NAD+ precursor | Yeast genetics and biochemistry identifying nicotinamide riboside kinase (NRK) genes | — | — | Identified NR as a third NAD+ precursor vitamin distinct from niacin and nicotinamide, establishing the Preiss, Handler-independent NRK salvage route conserved from fungi to humans 29. Foundational paper for the entire NR therapeutic field. |
| Belenky et al. (2007, Cell), NR extends lifespan via Sir2 in yeast | Yeast genetic study of NR salvage pathways and Sir2-dependent lifespan | — | — | Exogenous NR extended replicative lifespan in S. cerevisiae via Nrk1 and Urh1/Pnp1/Meu1 pathways feeding NAD+ for Sir2-mediated silencing 30. Mechanistic link from NR salvage to sirtuin-dependent longevity. |
| Berven et al. (2023, Nature Communications), NR-SAFE high-dose NR in Parkinson disease | Randomized, double-blind, placebo-controlled safety trial of high-dose NR 3000 mg/day in Parkinson disease | 20 | 4 weeks | High-dose NR was safe and well-tolerated in PD patients with no serious adverse events. Brain NAD+ rose on 31P-MRS; tolerability comparable to placebo. Extends NADPARK safety envelope to a higher dose 49. |
| Chen et al. (2015, NEJM), ONTRAC oral nicotinamide for skin-cancer chemoprevention | Randomized, double-blind, placebo-controlled trial of oral nicotinamide 500 mg twice daily in high-risk patients with prior nonmelanoma skin cancers | 386 | 12 months | Nicotinamide reduced new nonmelanoma skin cancers by 23% vs placebo. Largest positive randomized endpoint trial of any vitamin-B3 family compound and the strongest precedent for chronic oral nicotinamide safety in adults 36. |
| Gale et al. (2004, Lancet), ENDIT nicotinamide for type 1 diabetes prevention | European Nicotinamide Diabetes Intervention Trial, randomized, double-blind, placebo-controlled trial of nicotinamide in islet-autoantibody-positive first-degree relatives at risk for type 1 diabetes | 552 | Median 5 years | Nicotinamide did not prevent or delay onset of type 1 diabetes 35. Negative for the primary endpoint, but established long-term high-dose nicotinamide safety in adults and adolescents. |
| Surjana et al. (2012, J Invest Dermatol), Oral nicotinamide for actinic keratoses | Two phase II randomized, double-blind, placebo-controlled trials of oral nicotinamide 500 mg once or twice daily in patients with actinic keratoses | 76 | 4 months | Nicotinamide reduced actinic keratosis counts by 29, 35% vs placebo 37. Established the dermatologic precedent that became ONTRAC. |
Mechanism detail
The biochemistry of NAD+ consumption underlies the aging hypothesis 19. Sirtuins (SIRT1 nuclear, SIRT3 mitochondrial, and others) deacetylate transcription factors and metabolic enzymes including FOXO3, PGC-1α, p53, and acetyl-CoA synthetases; the reaction obligately cleaves NAD+ and releases nicotinamide 6318. PARP1 polyADP-ribosylates DNA-damage targets and chromatin proteins. CD38 hydrolyzes NAD+ to ADP-ribose or cyclic-ADP-ribose at the plasma membrane and in lysosomes; CD38 has emerged as the dominant NADase responsible for age-related tissue NAD+ decline, and selective inhibition with small molecules such as 78c restores tissue NAD+ and reverses age-related metabolic dysfunction in mice 4041. Each consumption event must be matched by biosynthetic resupply for steady-state NAD+ to be preserved.
The NAD+/sirtuin axis converges on mitochondrial biology. Mouchiroud et al. (2013) showed in C. elegans and mammalian cells that NAD+ repletion activates the mitochondrial unfolded protein response (UPR-mt) and FOXO signaling via SIR-2.1, extending lifespan in worms 33. Cantó et al. (2012) demonstrated in mice that oral NR enhances oxidative metabolism via SIRT1/SIRT3 activation and protects against diet-induced obesity 32 19. The framework that emerged, restore NAD+, reactivate sirtuin signaling, restore mitochondrial function, is the proximal motivation for human precursor trials.
Age-associated NAD+ decline is now documented in multiple tissues 19. Massudi et al. (2012) measured NAD+, NADH, NAD/NADH ratio, and PARP activity across the human lifespan in skin samples and showed a clear decline with age, accompanied by rising oxidative stress markers 5. Camacho-Pereira et al. (2016) traced age-related NAD+ decline in mouse tissues to upregulation of CD38, and demonstrated that CD38 knockout protected against the decline and against age-associated mitochondrial dysfunction in a SIRT3-dependent manner 7. The Bonkowski, Sinclair commentary framed the implication: NAD+ does not run out, it is destroyed faster than it is replaced 8. Brain-specific NAD+ decline and its role in neurodegeneration has been reviewed in detail 44.
The biology of the precursors 19. Nicotinamide riboside was identified as a distinct NAD+ precursor vitamin by Bieganowski and Brenner in 2004 29, with Belenky et al. (2007) demonstrating that NR extends lifespan via Sir2 in yeast through Nrk and Urh1/Pnp1/Meu1 salvage pathways 30. NR enters the mammalian cell via equilibrative nucleoside transporters, is phosphorylated by NRK1/NRK2 to NMN, and adenylated by NMNAT enzymes to NAD+ 23. NMN can enter cells via multiple routes including, in some tissues, the SLC12A8 transporter; intracellularly NMN is adenylated directly to NAD+. Nicotinamide can be recycled to NMN by NAMPT (the rate-limiting salvage enzyme), and nicotinic acid feeds the Preiss, Handler pathway. The de novo (kynurenine) route from tryptophan provides a minor but non-trivial input under most dietary conditions.
Pharmacologically, oral NR and NMN do not deliver intact NAD+ to tissues 19. Liver and gut are the principal first-pass sites of conversion; a substantial fraction of administered NR is rapidly methylated to N-methylnicotinamide and excreted, raising the methyl-group sink concern that high-dose chronic precursor loading could compete with other methylation pathways 9. The systemic NAD+ rise observed in whole blood and PBMCs reflects increased substrate supply rather than direct delivery of the dinucleotide; tissue-level uptake remains the principal pharmacological question. Elhassan et al. (2019) provided the first direct evidence that oral NR raises the intramuscular NAD+ metabolome in aged humans on biopsy, with concurrent transcriptomic anti-inflammatory signatures 43.
IV NAD+, by contrast, infuses the intact dinucleotide. Grant et al. (2019) showed in a 6-hour infusion pilot that plasma NAD+ rises in a delayed and dose-dependent way, with parallel rises in NAD+ metabolites in plasma and urine 15; the kinetics suggest extensive extracellular metabolism of infused NAD+ to nicotinamide and downstream precursors, which may then be salvaged intracellularly 19. Whether IV NAD+ confers a tissue-level NAD+ benefit distinct from oral precursor dosing has not been established in controlled human trials.
Pharmacology
Oral nicotinamide riboside is absorbed in the small intestine and undergoes extensive first-pass hepatic conversion. Trammell et al. (2016) 9 characterized the human PK: single-dose blood NAD+ metabolome rises in a dose-dependent way at 100, 300, and 1000 mg, with the rise persisting for hours. Chronic dosing studies 1314 show steady-state elevation of PBMC NAD+ that returns to baseline after discontinuation. Oral NMN PK in humans is less fully characterized but similarly shows dose-dependent blood NAD+ rise 202223.
Intravenous NAD+ PK was characterized by Grant et al. (2019) 15 in a single open-label pilot. An infusion of 750 mg NAD+ over 6 hours in 11 healthy adults produced delayed plasma NAD+ rise (not paralleling the infusion rate), with concurrent rise in plasma and urinary metabolites (nicotinamide, methylnicotinamide, NAAD, ADPR). The delayed kinetics suggest extensive extracellular metabolism of infused NAD+ to nicotinamide and salvage-pathway intermediates, which may then be taken up and resalvaged intracellularly. No human study has characterized tissue-level NAD+ delivery after IV NAD+ infusion.
Pharmacodynamic endpoints studied in NAD+-axis trials include blood and PBMC NAD+ and NAD+-metabolome elevation (consistently demonstrated across NR and NMN trials), muscle insulin sensitivity (improved in Yoshino 2021 NMN trial, not improved in NR trials in metabolic disease), mitochondrial respiration in skeletal muscle (not improved in Dollerup 2020 NR trial), body composition and acetylcarnitine concentrations (modest shifts in Remie 2020 NR trial), and brain NAD+ on 31P-MRS (elevated in NADPARK NR trial in Parkinson disease) 161720.
The pattern is consistent: NAD+ rises in blood reliably; tissue-level functional consequences are variable and context-dependent. The pharmacodynamic case for IV NAD+ is least developed, no controlled functional-endpoint trial of IV NAD+ has been published 13 2115.
Storage
Compounded sterile NAD+ solutions are stored refrigerated (2, 8°C) and protected from light per the pharmacy's stability data and beyond-use date assignment under USP <797> 27. NAD+ is sensitive to pH, oxidation, and light, so excipient buffering and container selection are documented per batch. Oral NR and NMN supplements are stored at room temperature per supplement label instructions.
RonanRx operations
Compounded NAD+ is prepared under 503A on patient-specific prescriptions in state-licensed compounding pharmacies 26. RonanRx prepares sterile injectable NAD+ preparations per USP General Chapter <797>, with documented active ingredient sourcing, gravimetric verification, sterility and endotoxin testing per the pharmacy's quality-management system, and full lot traceability 27. For nonsterile preparative steps the corresponding USP General Chapter <795> applies; the finished injectable product is governed by <797> 28.
Beyond-use dating, ingredient identity verification, sterility assurance, and stability assessment follow USP <797> requirements. Each compounded batch is documented per state board of pharmacy retention rules with full traceability from API lot through dispensing.
Each prescription for compounded NAD+ undergoes pharmacist review prior to dispensing 26. The review confirms: a documented patient-specific clinical reason and clinician-directed protocol (not a DTC longevity request); concentration and dose appropriate for the prescribed route (IV, IM, SC); absence of contraindicating clinical conditions in the available history; and concurrent medication review for theoretical interactions (active chemotherapy, immunosuppression).
RonanRx does not fill prescriptions that present as routine DTC wellness or longevity drip protocols without a documented clinician indication. The Tier-3 emerging evidence base for IV NAD+ in clinical use 15 makes the pharmacist review threshold particularly important 26.
Active pharmaceutical ingredient (NAD+, typically as the disodium salt) is sourced from FDA-registered facilities with documented certificates of analysis including identity, potency, and limits on heavy metals and microbial contaminants. Each compounded batch is recorded with lot numbers traceable to API source, compounding date, beyond-use date, sterility and endotoxin test results, and dispensing pharmacist of record. Finished product lot records are retained per state board of pharmacy retention requirements.
Compounded sterile injectable NAD+ is a cold-chain product. Refrigerated transport is used between the compounding pharmacy and the patient or prescribing clinic, with temperature monitoring through the shipment. Patients and clinics are advised to refrigerate the product on arrival, to inspect for temperature excursions, and to contact the pharmacy if cold-chain integrity is in question. NAD+ solutions are also light-sensitive; original packaging should be preserved until administration.
FAQ
No. There is no FDA-approved NAD+, NR, or NMN drug product 26. Niacin (nicotinic acid) is FDA-approved as Niaspan for dyslipidemia, but that is the cholesterol indication of the B3 vitamin and not an 'NAD+ booster' indication 24. NR (NIAGEN) is sold as a GRAS dietary supplement 25. Compounded NAD+ injections are 503A patient-specific preparations, not FDA-approved drugs.
Across multiple randomized trials, oral NR and NMN reliably raise blood and PBMC NAD+ levels in dose-dependent fashion 202223. Effects on clinical endpoints have been mixed: one positive metabolic endpoint (Yoshino 2021 NMN improved muscle insulin sensitivity in prediabetic postmenopausal women) and several null findings in metabolic disease cohorts on NR 1617 14. NR raised brain NAD+ in early Parkinson disease (NADPARK) 21 913.
One peer-reviewed human pharmacokinetic pilot: Grant et al. (2019), a 6-hour infusion of 750 mg NAD+ in 11 healthy adults 15. Plasma NAD+ rose with delayed kinetics and the metabolite signature suggested extensive extracellular metabolism. Beyond that, the clinical literature on IV NAD+ is anecdotal case-series. No controlled clinical-endpoint trial of IV NAD+ has been published.
No. RonanRx compounds NAD+ under 503A only on a patient-specific prescription from a licensed clinician with a documented clinical reason and protocol. We do not market or dispense IV NAD+ as a DTC longevity or wellness drip product 26.
No. Niacin (nicotinic acid) is a B3 vitamin and a precursor that feeds into NAD+ biosynthesis through the Preiss, Handler pathway, but it is not NAD+ itself 3. Niaspan (extended-release niacin) is the FDA-labeled product in dyslipidemia, not an NAD+-raising indication 24. NR and NMN are different B3-family precursors that feed the salvage pathway. Compounded NAD+ is the intact dinucleotide 1.
Multiple mechanisms appear to contribute, but the best-characterized driver is increased activity of CD38, an NAD+-consuming glycohydrolase that rises with age and inflammation 7. NAD+ is not 'running out' so much as being destroyed faster than it is replaced 8. PARP activation from accumulated DNA damage and sirtuin consumption also contribute 519.
Clinician resource
The full white paper covers every section on this page plus chemical identity, evidence grading, indication-by-indication summaries, research gaps, and reference appendix. Suitable for sharing with prescribing doctors and pharmacist reviewers.
References
How to access
Compounded NAD+ / NMN is dispensed under 503A on a patient-specific prescription. Pick the path that matches where you're starting from.
For doctors
A pharmacist will follow up within two business days. We'll cover state availability, supported formulations, and what integration looks like for your clinic.
Patient with a doctor
If your doctor has already prescribed NAD+ / NMN, sign up so we can prepare and ship your medication. The signup wizard collects intake and connects you to the prescribing workflow.
Patient without a doctor
RonanRx prescribes through partner clinics — we don't initiate prescriptions on this site. See how the referral works and how to find a clinic in your state that has evaluated patients for NAD+ / NMN.
Related